XML 42 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions, License Agreements and Other Investments Tables
3 Months Ended
Mar. 30, 2018
Business Combinations [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]
The following amounts represent the preliminary allocations of the fair value of the identifiable assets acquired and liabilities assumed for the Sucampo Acquisition, including preliminary goodwill, intangible assets and the related deferred tax balances. The Company expects to complete its valuation analysis and finalize deferred tax balances as of the acquisition date no later than twelve months from the date of the acquisition. The changes in the purchase price allocation and preliminary goodwill based on the final valuation may include, but are not limited to, finalization of working capital settlements, the impact of U.S. state tax rates in determining the deferred tax balances and changes in assumptions utilized in the preliminary valuation report.
 
 
Cash and cash equivalents
$
149.6

Accounts receivable
35.7

Inventory
153.2

Intangible assets
919.5

Goodwill
242.8

Other assets, current and non-current
24.8

Total assets acquired
1,525.6

Current liabilities
107.9

Deferred tax liabilities, net (non-current)
170.1

Total debt
366.3

Other noncurrent liabilities
33.7

Total liabilities assumed
678.0

Net assets acquired
$
847.6

Business Combination, Reconciliation of Total Consideration [Table Text Block]
The following is a reconciliation of the total consideration to net assets acquired:
 
 
Total consideration, net of cash
$
698.0

Plus: cash assumed in acquisition
149.6

Total consideration/net assets acquired
$
847.6

Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]
Intangible assets acquired consist of the following:
 
 
Amount
 
Amortization Period
 
Discount Rate
Completed technology - Amitiza
 
$
634.0

 
9 years
 
14.0%
Completed technology - Rescula
 
11.0

 
8 years
 
14.0%
In-process research and development - VTS 270
 
274.5

 
Non-Amortizable
 
15.0%
Business Combination, Earnings by Acquiree Allocation [Table Text Block]
Financial Results - The amount of net sales and loss included in the Company's results for the periods presented were as follows:
 
Three Months Ended
 
March 30, 2018
 
March 31, 2017
Net sales
$
24.2

 
$

Operating loss
(30.7
)